Steve Vucic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2852940/publications.pdf

Version: 2024-02-01

195 papers	11,200 citations	36303 51 h-index	33894 99 g-index
201 all docs	201 docs citations	201 times ranked	10562 citing authors

#	Article	IF	Citations
1	Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2022, 65, 43-50.	2.2	6
2	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.7	4
3	The split-elbow index: A biomarker of the split elbow sign in ALS. Clinical Neurophysiology Practice, 2022, 7, 16-20.	1.4	4
4	Long read sequencing overcomes challenges in the diagnosis of <scp>SORD</scp> neuropathy. Journal of the Peripheral Nervous System, 2022, 27, 120-126.	3.1	6
5	Differences in nerve excitability properties across upper limb sensory and motor axons. Clinical Neurophysiology, 2022, 136, 138-149.	1.5	2
6	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
7	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
8	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Multiple Sclerosis Journal, 2021, 27, 465-474.	3.0	23
9	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
10	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
11	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
12	Pathophysiological associations of transcallosal dysfunction in ALS. European Journal of Neurology, 2021, 28, 1172-1180.	3.3	12
13	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	9.0	79
14	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
15	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
16	Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis. Scientific Reports, 2021, 11, 2172.	3.3	12
17	Neurotoxicity and ALS: Insights into Pathogenesis. , 2021, , 1-19.		0
18	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open, 2021, 11, e041479.	1.9	33

#	Article	IF	Citations
19	Advances in the understanding of sensory neuronopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 343-343.	1.9	0
20	P300 jitter latency, brain-computer interface and amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 614-615.	1.5	1
21	Blunted sweating does not alter the rise in core temperature in people with multiple sclerosis exercising in the heat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R258-R267.	1.8	9
22	Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy. Journal of the Neurological Sciences, 2021, 423, 117358.	0.6	27
23	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. Neurology, 2021, 96, e2090-e2097.	1.1	12
24	Expression of CYP24A1 and other multiple sclerosis risk genes in peripheral blood indicates response to vitamin D in homeostatic and inflammatory conditions. Genes and Immunity, 2021, 22, 227-233.	4.1	3
25	Utility of Transcranial Magnetic Simulation in Studying Upper Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. Brain Sciences, 2021, 11, 906.	2.3	4
26	The Upper Motor Neuronâ€"Improved Knowledge from ALS and Related Clinical Disorders. Brain Sciences, 2021, 11, 958.	2.3	3
27	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
28	073â€…Headaches of raised intracranial pressure as a presenting feature of malignant infiltration in the cauda equina. , 2021, , .		0
29	The effectiveness of natalizumab vs fingolimodâ€"A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
30	036â€…Nerve excitability and motor unit number estimation: early biomarkers of nerve involvement in hereditary amyloidosis (ATTRv). , 2021, , .		0
31	008â€…Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. , 2021, , .		1
32	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537.	2.2	16
33	Review Article â€œSpotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Dateâ€• International Journal of General Medicine, 2021, Volume 14, 4579-4604.	1.8	7
34	Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. Neuroscience Letters, 2021, 759, 136039.	2.1	24
35	Measuring Tremorâ€"A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating. Movement Disorders, 2021, 36, 2962-2963.	3.9	3
36	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999.	3.7	18

#	Article	IF	Citations
37	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
38	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	2.4	8
39	Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41.	3.1	2
40	Split-hand index: A diagnostic and prognostic marker in amyotrophic lateral sclerosis across varying regions of onset. Clinical Neurophysiology, 2021, 132, 2130-2135.	1.5	7
41	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	2.2	13
42	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
43	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	1.5	63
44	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
45	ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology, 2020, 94, e1657-e1663.	1.1	39
46	Interneuronal networks mediate cortical inhibition and facilitation. Clinical Neurophysiology, 2020, 131, 1000-1010.	1.5	11
47	Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet Journal of Rare Diseases, 2020, 15, 70.	2.7	32
48	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	2.4	27
49	Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study). Medicine (United States), 2020, 99, e18904.	1.0	23
50	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	3.6	17
51	A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin. Muscle and Nerve, 2020, 62, E44-E45.	2.2	1
52	AANEM â€“ IFCN glossary of terms in neuromuscular electrodiagnostic medicine and ultrasound. Clinical Neurophysiology, 2020, 131, 1662-1663.	1.5	8
53	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 1373-1382.	3.7	19
54	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 532-537.	1.7	22

#	Article	IF	Citations
55	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 595-604.	1.7	63
56	Is Motor Unit Number Index (MUNIX) an index of Compound Muscle Action Potential amplitude rather than motor unit number?. Clinical Neurophysiology, 2019, 130, 1686-1687.	1.5	1
57	Inherited Neuropathies. Seminars in Neurology, 2019, 39, 620-639.	1.4	8
58	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 2019, 7, 145.	5.2	71
59	Amyotrophic lateral sclerosis diagnostic index. Neurology, 2019, 92, e536-e547.	1.1	17
60	Motor neuron disease with malignancy: Clinical and pathophysiological insights. Clinical Neurophysiology, 2019, 130, 1557-1561.	1.5	0
61	Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques. International Journal of Molecular Sciences, 2019, 20, 2818.	4.1	84
62	Immune checkpoint inhibitors and neuropathy: A new dawn. Clinical Neurophysiology, 2019, 130, 1401-1402.	1.5	0
63	Split elbow sign: more evidence for the importance of cortical dysfunction in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 729-729.	1.9	10
64	Conduction block in immuneâ€mediated neuropathy: paranodopathy versus axonopathy. European Journal of Neurology, 2019, 26, 1121-1129.	3.3	19
65	038â€...Tremor: a clinical and neurophysiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A13.2-A13.	1.9	0
66	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
67	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
68	Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. Journal of Clinical Neuroscience, 2019, 59, 229-231.	1.5	5
69	â€œTaming the Beastâ€: Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach. Research and Theory for Nursing Practice, 2019, 33, 229-245.	0.4	1
70	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
71	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
72	Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 681.	9.0	120

#	Article	IF	Citations
73	Role Of spinal mechanisms in the pathophysiology of the split hand sign in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 470-471.	2.2	0
74	Physiological changes in neurodegeneration â€" mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271.	10.1	72
75	Hypermetabolism appears to be an adverse prognostic biomarker in amyotrophic lateral sclerosis: a potential for therapeutic intervention?. European Journal of Neurology, 2018, 25, 1-2.	3.3	8
76	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 127-137.	1.9	422
77	Dysphagia in Multiple Sclerosis: Evaluation and Validation of the DYMUS Questionnaire. Dysphagia, 2018, 33, 273-281.	1.8	16
78	Neurofascinâ€155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. Muscle and Nerve, 2018, 57, 848-851.	2.2	37
79	Management of â€˜surplus sufferingâ€™ in relapsing remitting multiple sclerosis to improve patient quality of life. British Journal of Neuroscience Nursing, 2018, 14, 265-271.	0.2	0
80	Utility of threshold tracking transcranial magnetic stimulation in ALS. Clinical Neurophysiology Practice, 2018, 3, 164-172.	1.4	51
81	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
82	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. Neurology, 2018, 91, e1669-e1676.	1.1	67
83	Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma. Neurohospitalist, The, 2018, 8, 191-193.	0.8	17
84	Neurophysiological biomarkers in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2018, 31, 640-647.	3.6	51
85	In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis. Journal of Physiology, 2018, 596, 5379-5396.	2.9	23
86	032â€…Neurological sequelae of immune checkpoint inhibitors: a case series. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A13.3-A14.	1.9	1
87	Cortical excitability varies across different muscles. Journal of Neurophysiology, 2018, 120, 1397-1403.	1.8	14
88	Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 2149-2154.	1.5	20
89	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	1.5	15
90	004â€…Mechanisms of nerve dysfunction in inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A3.1-A3.	1.9	0

#	Article	IF	Citations
91	Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1141.	2.4	23
92	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
93	Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483.	1.9	93
94	The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis. Journal of Autoimmunity, 2017, 78, 57-69.	6.5	31
95	Prominent subcutaneous oedema as a masquerading symptom of an underlying inflammatory myopathy. Internal Medicine Journal, 2017, 47, 217-221.	0.8	4
96	Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 2017, 264, 882-890.	3.6	23
97	Physiological processes influencing motor-evoked potential duration with voluntary contraction. Journal of Neurophysiology, 2017, 117, 1156-1162.	1.8	23
98	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
99	Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis. European Journal of Neurology, 2017, 24, 816-824.	3.3	57
100	Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 2017, 309, 41-46.	2.3	44
101	Cortical function and corticomotoneuronal adaptation in monomelic amyotrophy. Clinical Neurophysiology, 2017, 128, 1488-1495.	1.5	9
102	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	1.9	108
103	Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Data in Brief, 2017, 11, 364-370.	1.0	10
104	Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 2017, 81, 355-368.	5.3	157
105	Isolated nerve plasmacytoma in a patient previously in systemic myeloma remission. Muscle and Nerve, 2017, 55, E27-E28.	2.2	0
106	Hyperpolarization-activated cyclic-nucleotide-gated channels potentially modulate axonal excitability at different thresholds. Journal of Neurophysiology, 2017, 118, 3044-3050.	1.8	9
107	Brain functional connectome abnormalities in amyotrophic lateral sclerosis are associated with disability and cortical hyperexcitability. European Journal of Neurology, 2017, 24, 1507-1517.	3.3	23
108	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 2017, 128, 2022-2028.	1.5	25

#	Article	IF	Citations
109	timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.11-e1.	1.9	0
110	Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics, 2017, 14, 91-106.	4.4	89
111	Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 2017, 55, 424-427.	2.2	10
112	Axonal Excitability in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 78-90.	4.4	43
113	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
114	Motor neurone disease: progress and challenges. Medical Journal of Australia, 2017, 206, 357-362.	1.7	28
115	Dissociation of Structural and Functional Integrities of the Motor System in Amyotrophic Lateral		

#	Article	IF	Citations
127	Motor Unit Number Index (MUNIX): A novel biomarker for ALS?. Clinical Neurophysiology, 2016, 127, 1938-1939.	1.5	2
128	Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 85-92.	1.7	32
129	Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. Clinical Neurophysiology, 2016, 127, 911-918.	1.5	22
130	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 470-482.	3.0	284
131	Rate of disease progression: a prognostic biomarker in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 628-632.	1.9	123
132	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2015, 2, 1916-1922.	6.1	25
133	Quantitative ultrasound of denervated hand muscles. Muscle and Nerve, 2015, 52, 221-230.	2.2	42
134	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	1.0	5
135	Axonal Ion Channel Dysfunction inC9orf72Familial Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 49.	9.0	35
136	Motor neuron disease: current management and future prospects. Internal Medicine Journal, 2015, 45, 1005-1013.	0.8	18
137	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, The, 2015, 14, 478-484.	10.2	164
138	Nerve ultrasound in detecting spinal nerve pathology in GBS: A novel diagnostic approach?. Clinical Neurophysiology, 2015, 126, 649-650.	1.5	5
139	Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2015, 126, 828-836.	1.5	26
140	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2015, 126, 803-809.	1.5	140
141	Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87124.	2.5	75
142	Apraxia and Motor Dysfunction in Corticobasal Syndrome. PLoS ONE, 2014, 9, e92944.	2.5	26
143	Nerve ultrasound in diabetic polyneuropathy: The new frontier?. Clinical Neurophysiology, 2014, 125, 657.	1.5	2
144	ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 2014, 125, 186-193.	1.5	44

#	Article	IF	Citations
145	Guillain-Barre syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 907-913.	1.9	63
146	Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 2014, 76, 643-657.	5.3	133
147	Facial onset sensory motor neuronopathy (FOSMN) syndrome: an unusual amyotrophic lateral sclerosis phenotype?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 951-951.	1.9	14
148	The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. Clinical Immunology, 2014, 151, 16-24.	3.2	49
149	Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in Neurosciences, 2014, 37, 433-442.	8.6	186
150	Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis. Journal of Visualized Experiments, 2014, , .	0.3	7
151	Motor cortical function and the precision grip. Physiological Reports, 2014, 2, e12120.	1.7	9
152	Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 2014, 21, 3535-3550.	2.4	9
153	Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 561-575.	1.8	34
154	Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1161-1170.	1.9	213
155	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2013, 124, 410-416.	1.5	97
156	Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 452-456.	1.7	2
157	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	7.6	123
158	Response to Karam et al.. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 159-160.	2.1	0
159	Cortical dysfunction underlies disability in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 425-432.	3.0	56
160	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2460-2467.	1.5	42
161	FOSMN syndrome. Neurology, 2012, 79, 73-79.	1.1	47
162	Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 414-420.	2.1	23

#	Article	IF	Citations
163	Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 2011, 122, 1860-1866.	1.5	122
164	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	13.7	2,182
165	Clarifying variability of corticomotoneuronal function in kennedy disease. Muscle and Nerve, 2011, 44, 197-201.	2.2	6
166	Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cerebral Cortex, 2011, 21, 1639-1644.	2.9	30
167	Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 222-227.	1.9	86
168	Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 97-100.	1.9	31
169	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	7.6	29
170	Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clinical Neurophysiology, 2010, 121, 1781-1785.	1.5	20
171	Fatigue in multiple sclerosis: Mechanisms and management. Clinical Neurophysiology, 2010, 121, 809-817.	1.5	97
172	Article Commentary: Dysfunction of Corticomotoneurons in Guillain-BarrÎ-Syndrome (GBS)?. Clinical Medicine Case Reports, 2009, 2, CCRep.S3553.	0.1	0
173	Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis. Current Molecular Medicine, 2009, 9, 255-272.	1.3	101
174	The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Research, 2009, 1273, 39-47.	2.2	67
175	Guillain-BarrÃ© syndrome: An update. Journal of Clinical Neuroscience, 2009, 16, 733-741.	1.5	224
176	Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 220, 177-182.	4.1	71
177	Dysfunction of Corticomotoneurons in Guillain-BarrÃ© Syndrome (GBS)?. Clinical Medicine Case Reports, 2009, 2, 59-61.	0.1	0
178	Normal axonal ion channel function in large peripheral nerve fibers following chronic ciguatera sensitization. Muscle and Nerve, 2008, 37, 403-405.	2.2	6
179	Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle and Nerve, 2008, 38, 1447-1454.	2.2	45
180	Cortical excitability testing distinguishes Kennedyâ€™s disease from amyotrophic lateral sclerosis. Clinical Neurophysiology, 2008, 119, 1088-1096.	1.5	74

#	Article	IF	Citations
181	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-1550.	7.6	391
182	Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 2007, 69, 1828-1835.	1.1	27
183	Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 849-852.	1.9	97
184	Multifocal motor neuropathy with conduction block: Distribution of demyelination and axonal degeneration. Clinical Neurophysiology, 2007, 118, 124-130.	1.5	25
185	Long-term effects of intravenous immunoglobulin in CIDP. Clinical Neurophysiology, 2007, 118, 1980-1984.	1.5	29
186	Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1202-1208.	1.9	54
187	Anterior interosseous nerve conduction study: Normative data. Muscle and Nerve, 2007, 35, 119-121.	2.2	13
188	Polyglucosan body disease myopathy: An unusual presentation. Muscle and Nerve, 2007, 35, 536-539.	2.2	10
189	Utility of magnetic resonance imaging in diagnosing ulnarneuropathy at the elbow. Clinical Neurophysiology, 2006, 117, 590-595.	1.5	74
190	Axonal excitability properties in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2006, 117, 1458-1466.	1.5	177
191	Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 2006, 33, 477-486.	2.2	162
192	Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain, 2006, 129, 3384-3390.	7.6	81
193	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-2446.	7.6	284
194	CMT with pyramidal features. Neurology, 2003, 60, 696-699.	1.1	36
195	Safety of plasmapheresis in the treatment of neurological disease. Australian and New Zealand Journal of Medicine, 1998, 28, 301-305.	0.5	30